HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

[Lung cancer].

Abstract
Postoperative adjuvant chemotherapy with tegafur-uracil has become the standard of care for patients with completely resected stage I adenocarcinoma according to the positive result from phase III trial conducted in Japan. The effectiveness of tegafur-gimeracil-oteracil potassium in advanced non-small cell lung cancer (NSCLC) is now under investigation in a phase III trial in the first-line treatment in combination with platinum agent as well as in second-line treatment as monotherapy. The evidence of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) such as gefitinib and erlotinib was first confirmed as the second-line treatment for non-selective patients with advanced NSCLC. However, now it is essential to examine some active EGFR gene mutations such as exon 19 deletion or L858R in exon 21, the novel predictive factor for high efficacy of EGFR-TKI, in terms of the risk-benefit balance. For patients with EGFR-mutated advanced NSCLC, the first-line treatment with gefitinib had achieved a significant prolongation of progression-free survival compared with standard platinum doublet chemotherapy in a few phase III trials, and became a new standard of care. Gefitinib is highly effective for patients with advanced NSCLC with EGFR mutation even if their performance status is poor, although one should always pay careful attention to fatal interstitial lung disease.
AuthorsAkira Inoue
JournalGan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 37 Issue 7 Pg. 1224-9 (Jul 2010) ISSN: 0385-0684 [Print] Japan
PMID20647703 (Publication Type: English Abstract, Journal Article)
Chemical References
  • Antineoplastic Agents
  • Protein Kinase Inhibitors
  • Quinazolines
  • EGFR protein, human
  • Receptor, Epidermal Growth Factor
  • gefitinib
Topics
  • Administration, Oral
  • Antineoplastic Agents (administration & dosage, therapeutic use)
  • Chemotherapy, Adjuvant
  • Clinical Trials, Phase III as Topic
  • Humans
  • Lung Neoplasms (drug therapy, genetics, metabolism)
  • Protein Kinase Inhibitors (therapeutic use)
  • Quinazolines (therapeutic use)
  • Receptor, Epidermal Growth Factor (antagonists & inhibitors, genetics, metabolism)
  • Survival Rate

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: